Search

Hutchison China MediTech Ltd ADR

Ouvert

SecteurSoins de santé

12.01 4.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.52

Max

12.42

Chiffres clés

By Trading Economics

Revenu

7M

8M

Ventes

3.7M

139M

P/E

Moyenne du Secteur

115.5

68.51

Marge bénéficiaire

5.724

Employés

1,790

EBITDA

18M

4M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+22.82% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

95M

2B

Ouverture précédente

7.76

Clôture précédente

12.01

Sentiment de l'Actualité

By Acuity

100%

0%

329 / 340 Classement par Healthcare

Hutchison China MediTech Ltd ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 août 2026, 23:56 UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

6 août 2026, 23:56 UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

6 août 2026, 23:52 UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

6 août 2026, 23:51 UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

6 août 2026, 23:51 UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

6 août 2026, 23:51 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

6 août 2026, 23:51 UTC

News

Fox Factory Holding Corp reported Q2 sales of $358.1 million, exceeding expectations. The company raised its full-year guidance, and shares advanced in after-market trading.

6 août 2026, 23:51 UTC

News
Social Media

Twilio Inc reported second-quarter revenue of $1.50 billion, exceeding estimates. Shares are trading sharply higher in after-market hours following the strong results.

6 août 2026, 23:51 UTC

News
Social Media

Indie Semiconductor reports second-quarter revenue of $64 million, exceeding estimates. Shares are trading higher in after-market hours on positive guidance for Q3.

6 août 2026, 23:51 UTC

News
Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

6 août 2026, 23:51 UTC

News
Social Media

Onto Innovation shares rose in after-market trading following record revenue of $343 million and adjusted EPS of $1.93, both exceeding analyst expectations.

6 août 2026, 23:51 UTC

News
Social Media

Airbnb Inc. reported second-quarter revenue of $3.61 billion, exceeding estimates. Shares rose significantly in after-market trading, despite earlier pulling back from a session high.

6 août 2026, 23:46 UTC

News
Social Media

Republic Services reported strong second-quarter earnings and raised full-year adjusted EPS guidance. The stock was trading roughly flat in after-market hours.

6 août 2026, 23:46 UTC

News

McDonald's shares are lower in after-market trading as CEO Chris Kempczinski discusses challenges with the company's value menu strategy and execution issues.

6 août 2026, 23:42 UTC

Social Media
News

DraftKings shares are lower in after-market hours following a net loss of $67.6 million and revenue that fell short of estimates.

6 août 2026, 23:41 UTC

News
Social Media

MP Materials reported second-quarter revenue of $108.5 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

6 août 2026, 23:41 UTC

News
Social Media

Doximity reported fiscal Q1 revenue of $156.6 million, exceeding expectations. The company raised its FY2027 revenue guidance, driving shares higher in after-hours trading.

6 août 2026, 23:41 UTC

News

nLIGHT Inc shares are sharply lower in after-market trading following mixed Q2 results and cautious guidance, projecting revenues below analyst expectations.

6 août 2026, 23:41 UTC

Social Media
Event
News

Dropbox Inc. shares declined in after-market trading despite reporting Q2 revenue of $631.5 million, exceeding expectations. Concerns over stagnant growth contributed to the drop.

6 août 2026, 23:36 UTC

News

First Business Financial Services Inc shares are higher in after-market hours, positioned near the upper end of their one-month trading range.

6 août 2026, 23:36 UTC

News

Navient Corp reported second quarter earnings of $0.26 per share, exceeding expectations, but shares are trading lower in after-market hours amid revenue decline.

6 août 2026, 23:36 UTC

News

Canaccord Genuity maintained its Hold rating on Zillow Group and lowered its price target to $40. Shares are trading roughly flat after market hours.

6 août 2026, 23:32 UTC

News

Insulet Corp shares are lower in after-market hours following a downgrade to Market Perform by Leerink Partners and a reduced price target of $145.

6 août 2026, 23:31 UTC

News

Arlo Technologies reported second-quarter revenue of $156 million and raised fiscal year 2026 guidance, contributing to a notable increase in after-market trading.

6 août 2026, 23:31 UTC

News
Social Media

Akamai Technologies reported second-quarter revenue of $1.1 billion and adjusted EPS of $1.59, both exceeding analyst expectations. The stock is higher in after-market trading.

6 août 2026, 23:31 UTC

News
Social Media

Figs Inc. reported second-quarter revenues of $196.6 million and raised its full-year growth forecast, contributing to a notable rise in after-market trading.

6 août 2026, 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

6 août 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

6 août 2026, 23:31 UTC

News
Social Media

Sweetgreen Inc. shares fell sharply in after-market trading following a significant net loss and revenue miss in its second-quarter results.

6 août 2026, 23:31 UTC

News
Social Media

Trade Desk Inc shares declined sharply after reporting second-quarter revenue of $715 million, missing expectations, and providing weak guidance for the third quarter.

Comparaison

Variation de prix

Hutchison China MediTech Ltd ADR prévision

Objectif de Prix

By TipRanks

22.82% hausse

Prévisions sur 12 Mois

Moyen 14.53 USD  22.82%

Haut 16 USD

Bas 13.6 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

1

Achat

2

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat